- Home
- Publications
- Publication Search
- Publication Details
Title
Development of CAR-T cell therapies for multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-23
DOI
10.1038/s41375-020-0930-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA
- (2020) Kodandaram Pillarisetti et al. BLOOD
- Autologous CAR T-cell therapies supply chain: challenges and opportunities?
- (2020) Maria M. Papathanasiou et al. CANCER GENE THERAPY
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
- (2020) Boris Fehse et al. Molecular Therapy-Methods & Clinical Development
- Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
- (2020) Julia Hambach et al. Cells
- Immunotherapy of multiple myeloma
- (2020) Simone A. Minnie et al. JOURNAL OF CLINICAL INVESTIGATION
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Pomalidomide‐Dexamethasone for Treatment of Soft Tissue Plasmacytomas in Patients with relapsed / refractory Multiple Myeloma
- (2019) Raquel Jiménez‐Segura et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- (2019) Yahiya Y. Syed DRUGS
- Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2019) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
- (2019) Maxime Jullien et al. ANNALS OF HEMATOLOGY
- Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications
- (2019) Sandra P. Susanibar Adaniya et al. AMERICAN JOURNAL OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
- (2019) Cesar Sommer et al. MOLECULAR THERAPY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Nico Gagelmann et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
- (2019) Lekha Mikkilineni et al. BLOOD
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
- (2019) Alfred L. Garfall et al. BLOOD
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis
- (2019) Nico Gagelmann et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- CAR T-cell therapy: is it prime time in myeloma?
- (2019) Surbhi Sidana et al. Hematology-American Society of Hematology Education Program
- Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation
- (2018) Maximilian Gröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
- (2018) Nico Gagelmann et al. HAEMATOLOGICA
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
- (2018) Eric L. Smith et al. MOLECULAR THERAPY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
- (2018) Nico Gagelmann et al. HAEMATOLOGICA
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases
- (2018) Wajid Hussain et al. GENE
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
- (2017) Leah Alabanza et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
- (2017) Ehsan Malek et al. Frontiers in Oncology
- Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
- (2016) Djordje Atanackovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
- (2016) M Sobh et al. LEUKEMIA
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Transcriptome Analysis of Fetal Skin Reveals Key Genes Related to Hair Follicle Morphogenesis in Cashmere Goats
- (2016) Ye Gao et al. PLoS One
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- How I treat extramedullary myeloma
- (2015) C. Touzeau et al. BLOOD
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent
- (2015) Camille Guillerey et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
- (2014) T Paíno et al. LEUKEMIA
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma
- (2013) Roman Hajek et al. BRITISH JOURNAL OF HAEMATOLOGY
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- CD38 and CD157: A long journey from activation markers to multifunctional molecules
- (2013) Valeria Quarona et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
- (2013) Markus Chmielewski et al. IMMUNOLOGICAL REVIEWS
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Integrated supply chain planning for multinational pharmaceutical enterprises
- (2012) Naresh Susarla et al. COMPUTERS & CHEMICAL ENGINEERING
- Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
- (2012) Johanna Atamaniuk et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
- (2012) YAWARA KAWANO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
- (2011) Joan Bladé et al. JOURNAL OF CLINICAL ONCOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now